0R, the Eclectic Workplace Acid Test

Total Page:16

File Type:pdf, Size:1020Kb

0R, the Eclectic Workplace Acid Test THE WORK R (0r,T The Eclectic WorkplaceIP Acid Test) In hep San Francisco, innovative office workers have found a new way to boost productivity: microdosing psychedelic performance enhancers during their 9-5. But can taking LSD really make you a better employee? To test the theory, one MH writer decided to trial his own weekday trip from COULD LSD ADD COLOUR the (relative) safety of his desk. This is what happened TO THE MONOTONE GUTTER CREDIT GUTTER OF YOUR DAILY GRIND? WORDS BY TOM WARD – PHOTOGRAPHY BY AGATA PEC 68 MEN’S HEALTH MENSHEALTH.CO.UK MENSHEALTH.CO.UK MEN’S HEALTH 69 THE IT’S 10AM WORK Tom is more prone to studied But on the second go the TRIP PROGRESS diligence than outbursts of effects were more noticeable. REPORT zany banter. So, even though Tom enjoyed distinct periods I was aware of his dosing, of down-time that split up his FRIDAY Will microdosing LSD at charting any changes in his work, seemingly thanks to in 2016 – is an altogether different feat. allowing the mind to settle before the work have your supervisor 9-5 demeanour was tricky. better focus on projects. In I tentatively message a friend whose cycle begins again on the fourth. Taken at readying your P45? MH’s In fact, by the end of the first meetings, his ideas were less Facebook photos feature variations this dose, LSD’s effect is ‘psycholytic’ as deputy editor, David Morton, Monday, I had forgotten he encumbered by overthinking. of him hanging about Indian temples opposed to psychedelic – mind-blowing charts our writer’s progress was ‘experimenting’ entirely. Which is a trip I’d like to take. arrayed in patterned sari pants as he in a way that won’t have you picturing bats gazes lustily at the sunset. He responds MORNINGand as the MH editorial team sits down swooping overhead. As Fadiman wrote, almost immediately promising to order for its daily meeting, every one of my “The rocks don’t glisten, not even a little.” my LSD from the ‘Dark Web’. Fadiman thoughts is focused on the tab of LSD was being sold in the US as a psychiatric Whether microdosed or ingested at recommends using liquid LSD, but the I’ve just ingested. None of my colleagues medication under the trade name Delysid. full strength, LSD works by stimulating only source online is selling 25 250mg know I’ve taken it and I am as yet unsure From the mid-’50s to 1973, the CIA got in the 5-HT2A receptors in the pre-frontal vials for £240, which equates to 6230 what its impact on my day – my career on the act, exploring the drug’s potential cortex, increasing the activity of glutamate more doses than I require. There’s also – will be. This isn’t a ploy to lose my job, use for mind control, while it was also – a substance vital to learning – with a risk that shelling out for that much will nor have I simply started the weekend being used by the American Psychiatric the resulting sensation mimicking the land me in trouble with the law, and early. If pioneering researchers across Association to treat alcoholism. effect of the release of feel-good chemical a certainty it’ll land me with some hefty the pond are to be believed, lysergic acid But concerns about the mind-altering serotonin. According to research in the overdraft charges. Instead we plump for diethylamide – LSD to you and me – is properties of LSD and its counter-culture Journal of Analytical Toxicology, LSD 10 tabs for £45, a mere 980 doses more simply the latest in a string of unusual following were growing. In a 1965 edition has a ‘plasma half-life’ of just over five than I’ll need. A week later an envelope products claimed as workplace aids. of The Harvard Crimson, Dr Max Rinkel hours, meaning an entire dose should be arrives in the post. I open it to find a According to one Harvard researcher, by – the first American doctor to work with cleared from your system inside 10 hours. folded card labelled “BDSM Porn – Please taking a miniscule amount at my desk LSD – was reported as having expressed Contrary to the popular doom-leaden HALLUCINOGENS MAY find your login info and selected vouchers I’m opening my brain up to receive ideas, concern over the long-term effects of mythos of the ’60s and ’70s, traces of ONE DAY USURP YOUR enclosed.” Labelling orders in this way is improve focus and sharpen creativity. the drug: “Rinkel said that the danger the drug won’t be stored in your spinal MORNING PICK-ME-UP a clever stratagem for avoiding detection, But this is no mere nootropic. Get the of taking LSD outside a hospital was that column for the rest or your life. Nor can but makes for a possibly relationship- dose wrong, or approach it in the wrong the size of the dosage and the purity of the the effects of the drug be accidentally shattering package to open with your frame of mind, and I may well be freaking drug are uncertain, and the reaction of triggered at a later date, turning you girlfriend standing beside you. Finding out not just at my workload, but at the any individual is somewhat uncertain. He into some kaleidoscopic Manchurian the brightly coloured tabs of LSD – a Class elephants carrying my P45 in their trunks cited the case of a woman who, after taking Candidate. On a normal, 100mg dose, A drug – inside comes as strange relief. as they float through my editor’s office. the drug, tore off her clothes and knelt a 12-hour trip will likely always be the Next, the tricky part. A single tab To find out what this means for my – before a thermostat, which she believed very limit of what your brain endures. of LSD is about a quarter of the size of for our – workplace prospects, I set out was a crucifix. The experiment was then Nor – contrary to popular belief – a postage stamp, and I need a tenth to microdose LSD once every four days, terminated.” is LSD chemically of that. I get the sharpest kitchen knife over the course of two working weeks, LSD’s inevitable addictive: “Before out and perform a surgical dissection. and record the results. Would I unlock ban came five years “By midday I’m a second dose can Never having taken LSD before, I’m the hitherto untapped potential of my later, in 1970, when yet to visualise have an impact, you apprehensive about getting this right. brain, entering a swirling mental vortex US president Richard need to leave your Even with this feature signed off by my in which words fly past my eyes as my Nixon signed tangerine trees or brain for a while to editor (and the company’s lawyers), I fingers spark against the keyboard? the Controlled marmalade skies” sort of reset,” says don’t imagine he’ll find me tripping balls Would the Pulitzer board be lining up Substances Act. Jonathan Liebling, in the office overly endearing. The next to canonise my next weightloss feature? The UK’s Misuse of Drugs Act followed political director of drug law campaigners day I meet Liebling for a coffee, hoping he And would I finally understand the in 1971. In the UK, LSD is now, along with The United Patients Alliance and LSD can allay my fears. “The effect of taking ending of Mad Men? To paraphrase the ecstasy and cannabis, a Schedule 1 drug – specialist at The Loop. “Because your 10-12mg will be no different to the late psychedelic pioneer Timothy Leary, defined as one with no therapeutic value body can’t build up a tolerance, it’s almost sugar in your tea,” he says. I decided to turn on, tune in and find out. and a high potential for abuse. It is highly impossible to become addicted.” Add that “Once you start going for 30- illegal, along with nearly all research into it. to the findings of two US studies in 2015 33% 40mg there’ll be a noticeable of subjects reported THE MAGICAL MYSTERY TOUR Yet in the states – specifically the tech that concluded there is no link between effect and, depending on LSD has a storied history both in and seats of Silicon Valley and San Francisco psychedelics and psychosis, and the long-term creative the person, 75-200mg is out of the laboratory. It was discovered – bored of Bulletproof coffees, biohacking historic and histrionic outcry about the benefits in a enough for a proper trip.” by Swiss scientist Albert Hofmann who, implants and efficiency-boosting fasting, drug’s dangers appear oversold. “The 1999 MAPS study I’m reminded of a Bill after isolating the chemical from the ergot a horde of young technologists are dosing acid is just the trigger that gives your into LSD Hicks line about people on fungus in 1938, accidentally sent himself their way to the top. Circuit board whizz brain a signal to turn up the volume,” says LSD jumping to their deaths on the world’s first acid trip. “I sank into Bill Gates is reported to have dabbled, Liebling. “Your brain would not respond from rooftops, believing they could a… extremely stimulated condition… but the lynchpin behind the move toward how it does if it were going to be harmed.” fly. Birds, Hicks points out, can also fly, I perceived an uninterrupted stream of creative dosing is Dr James Fadiman, but often take off from the ground.
Recommended publications
  • Annual Report 2018 -2019
    ANNUAL REPORT 2018 -2019 the beckley foundation annual report CONTENTS ABOUT THE FOUNDATION UPCOMING RESEARCH 1 1 3 MESSAGE FROM THE DIRECTOR SCIENTIFIC PUBLICATIONS 2 14 UN SUSTAINABILITY GOALS DRUG POLICY REFORM 3-4 15-18 ADVISORY BOARD ACCESS 5-6 19 SCIENCE EVENTS & MEDIA BECKLEY/BRAZIL 7-8 20-22 BECKLEY/IMPERIAL FUNDING 9-10 22 BECKLEY/MAASTRICHT COLLABORATIONS 11-12 23 BECKLEY/ICEERS THANK YOU 12 24 11 ABOUT THE BECKLEY FOUNDATION Mission Our aim is to harness the power of science in order to integrate psychoactive substances into society as safe & effective tools to treat a broad range of health conditions and to enhance wellbeing. Amanda Feilding Amanda Feilding has been studying the mechanisms underlying the effects of psychedelics since 1966. In 1998, she set up the Beckley Foundation in order to open up the doors of scientific research into the potential benefits of psychedelics, and to develop a scientific evidence base to help reform global drug policies, so that these compounds can be made available to patients in need. The Three Pillars of the Beckley Foundation Science Policy Access The Beckley Foundation’s The Policy Programme Access provides Scientific Programme, provides a rigorous, Amanda Feilding with led by Amanda Feilding, independent review a platform to deliver develops and conducts of current global drug on her goal to develop psychedelic research policies, and for over innovative solutions through an international 20 years has been that ensure psychedelic network of collaborative developing a scientific treatments are made partnerships with leading evidence-base on available for those in scientists and institutions which to build balanced need, in the years ahead.
    [Show full text]
  • CANNABIS Policy: Moving Beyond Stalemate
    PRESS RELEASE CANNABIS Policy: Moving Beyond Stalemate On Thursday, 2nd October 2008, the Beckley Foundation will launch its Global Cannabis Commission Report, an authoritative guide to the effects of cannabis, the policies that control its use, and recommendations for policy reform. Despite cannabis being the most widely used illegal drug, with more than 160 million users worldwide, and therefore being the mainstay of the War on Drugs, it has only held a relatively marginal position in international drug policy discussions. In recognition of this, Amanda Feilding, Director of the Beckley Foundation decided to convene a team of the world’s leading drug policy analysts to prepare an overview of the latest scientific evidence surrounding cannabis and the policies that control its use. The Beckley Foundation is a UN-accredited NGO and this Report has been prepared for the United Nations’ Strategic Drug Policy Review of 2009. The Report will provide policy-makers at national and international level with all the relevant facts to help them make better informed decisions. In reviewing the evidence, the authors come to some striking conclusions, many of which challenge the received wisdom concerning cannabis: • Although cannabis can have a negative impact on health, including mental health, in terms of relative harms it is considerably less harmful than alcohol or tobacco. Historically there have only been 2 deaths worldwide attributed to cannabis, whereas alcohol and tobacco together are responsible for over 100,000 deaths per annum in the UK alone. • Many of the harms associated with cannabis use are the result of prohibition itself, particularly the social harms arising from arrest and imprisonment.
    [Show full text]
  • Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up
    Psychopharmacology https://doi.org/10.1007/s00213-017-4771-x ORIGINAL INVESTIGATION Psilocybin with psychological support for treatment-resistant depression: six-month follow-up R. L. Carhart-Harris1 & M. Bolstridge1,2 & C. M. J. Day1,2 & J. Rucker 1,3,4 & R. Watts1 & D. E. Erritzoe1 & M. Kaelen1 & B. Giribaldi1 & M. Bloomfield5 & S. Pilling6 & J. A. Rickard7 & B. Forbes8 & A. Feilding9 & D. Taylor10 & H. V. Curran6,11 & D. J. Nutt1 Received: 13 July 2017 /Accepted: 19 October 2017 # The Author(s) 2017. This article is an open access publication Abstract for the first 5 weeks post-treatment (Cohen’s d = 2.2 at week 1 Rationale Recent clinical trials are reporting marked improve- and 2.3 at week 5, both p < 0.001); nine and four patients met the ments in mental health outcomes with psychedelic drug-assisted criteria for response and remission at week 5. Results remained psychotherapy. positive at 3 and 6 months (Cohen’s d = 1.5 and 1.4, respectively, Objectives Here, we report on safety and efficacy outcomes for both p < 0.001). No patients sought conventional antidepressant up to 6 months in an open-label trial of psilocybin for treatment- treatment within 5 weeks of psilocybin. Reductions in depressive resistant depression. symptoms at 5 weeks were predicted by the quality of the acute Methods Twenty patients (six females) with (mostly) se- psychedelic experience. vere, unipolar, treatment-resistant major depression re- Conclusions Although limited conclusions can be drawn ceived two oral doses of psilocybin (10 and 25 mg, 7 days about treatment efficacy from open-label trials, tolerability apart) in a supportive setting.
    [Show full text]
  • An Update from the Beckley Foundation AMANDA FEILDING
    MAPS Bulletin Annual Report Reforming Psychedelic Science and Policy: An Update from the Beckley Foundation AMANDA FEILDING Amanda Feilding THE BECKLEY FOUNDATION HAS HAD a very successful year, with that the changes in connectivity between brain regions brought much progress on our dual fronts of Science and Policy. about by psilocybin resemble those seen during meditation and In January the Beckley Foundation–Imperial College Psy- early psychosis: The networks responsible for inner focus and chedelic Research Programme published two ground-breaking external attention, normally acting in opposition to one another, scienti!c papers on the e"ects of psilocybin on cerebral blood become more closely coupled. This can result in a blurring #ow and brain activity, using brain-imaging technology corre- between “inner” and “outer” worlds in all these states—for lated with subjective reports. The !ndings reveal how psilocybin example the “ego-dissolution” and “unitary state of awareness” decreases blood #ow and thereby diminishes the activity of a reported both after taking psychedelics and in the mystical state. network of key “hub centres,” which are responsible for !lter- Another Beckley/Imperial study, into the neural basis of ing and coordinating information. By decreasing this censoring the e"ects of MDMA, was televised in September on Channel 4 activity, psilocybin allows a freer, less constrained state of con- in the UK and watched by over two million people. In response sciousness to emerge. to positive memories, MDMA was found to increase the response One of the “hubs” deprived of blood #ow by psilocybin is of the brain’s sensory cortex.
    [Show full text]
  • NPS Amanda Feilding & Nicola Singleton TBC
    UK PRESS RELEASE - STRICT EMBARGO UNTIL 26.05.16 Roadmaps to Regulation: NPS Amanda Feilding & Nicola Singleton TBC Funded By OSF & Getty Foundation Amanda Feilding and the Beckley Foundation have released the Novel Psychoactive Substances chapter of its upcoming report, “Roadmaps to Regulation: Cannabis, MDMA, Psychedelics and Novel Psychoactive Substances”. The launch of this chapter on 26 May 2016 coincides with the date that the latest piece of scientifically illiterate legislation comes into force: The Psychoactive Substances Act 2016. The report condemns the UK Government’s approach of introducing a blanket ban on the supply and production of psychoactive substances as scientifically ill-founded, legally dubious, misguided and potentially harmful. The Beckley Foundation offer an alternative option similar to the system in New Zealand, which would allow new psychoactive substances to go through safety trials, and those drugs which proved low-risk would be made available for sale in a strictly regulated legal market. The UK is undergoing a growing problem with “legal highs”, particularly the use of synthetic cannabinoids such as “Spice” and “Black Mamba.” Rather than addressing the root issue, an unabated demand for cannabis, the Government has attempted to ban all psychoactive substances. This will drive producers and retailers underground, funding criminal organisation, increasing the harms associated with drug use and not reducing the use of psychoactive substances. Amanda Feilding comments, “The explosion of NPS is a result of the prohibition of the classical psychoactive substances, such as cannabis, MDMA, psychedelics and stimulants. If there was legal regulation of these substances, there would be no need for the creation of new, and most often inferior imitations”.
    [Show full text]
  • The Rise and Decline of Cannabis Prohibition the History of Cannabis in the UN Drug Control System and Options for Reform
    TRANSNATIONAL I N S T I T U T E THE RISE AND DECLINE OF CANNABIS PROHIBITION THE HISTORY OF CANNABIS IN THE UN DruG CONTROL SYSTEM AND OPTIONS FOR REFORM 3 The Rise and Decline of Cannabis Prohibition Authors Dave Bewley-Taylor Tom Blickman Martin Jelsma Copy editor David Aronson Design Guido Jelsma www.guidojelsma.nl Photo credits Hash Marihuana & Hemp Museum, Amsterdam/ Barcelona Floris Leeuwenberg Pien Metaal UNOG Library/League of Nations Archives UN Photo Printing Jubels, Amsterdam Contact Transnational Institute (TNI) De Wittenstraat 25 1052 AK Amsterdam Netherlands Tel: +31-(0)20-6626608 Fax: +31-(0)20-6757176 [email protected] www.tni.org/drugs www.undrugcontrol.info www.druglawreform.info Global Drug Policy Observatory (GDPO) Research Institute for Arts and Humanities Rooms 201-202 James Callaghan Building Swansea University Financial contributions Singleton Park, Swansea SA2 8PP Tel: +44-(0)1792-604293 This report has been produced with the financial www.swansea.ac.uk/gdpo assistance of the Hash Marihuana & Hemp Museum, twitter: @gdpo_swan Amsterdam/Barcelona, the Open Society Foundations and the Drug Prevention and Information Programme This is an Open Access publication distributed under (DPIP) of the European Union. the terms of the Creative Commons Attribution License The contents of this publication are the sole responsibility (http://creativecommons.org/licenses/by/2.0), which of TNI and GDPO and can under no circumstances be permits unrestricted use, distribution, and reproduction regarded as reflecting the position of the donors. in any medium, provided the original work is properly cited. TNI would appreciate receiving a copy of the text in which this document is used or cited.
    [Show full text]
  • PRESS RELEASE Clinical Study Into LSD Microdosing Shows Strong Pain Management Potential 26Th August 2020, Oxford, UK / Maastricht, NL
    PRESS RELEASE Clinical Study into LSD Microdosing Shows Strong Pain Management Potential 26th August 2020, Oxford, UK / Maastricht, NL Beckley/Maastricht research team finds pain application for ‘non-psychedelic’ LSD microdosing The first study of its kind to test the potential of LSD as an analgesic since the 1960s Further studies could lead to possible application of LSD as a non-addictive pain medication A new UK and European placebo-controlled clinical study completed by the Beckley Foundation and Maastricht University has shown that low doses of the psychedelic compound lysergic acid diethylamide (LSD) may provide a viable, non-addictive alternative for pain management. The Beckley/Maastricht Microdosing Research Programme was set up to study the effects of small doses (commonly referred to as ‘microdoses’) of LSD on humans, with a particular focus on mood, cognitive functions, and pain management. The study, which was the first in a series of research projects, saw twenty-four healthy volunteers each receive single doses of 5, 10 and 20 micrograms of LSD, or a placebo. Among other measures collected throughout the dosing days, pain tolerance levels were assessed using a Cold Pressor Test, a valid and low-risk test for evaluating individual pain thresholds which involves the use of a tank filled with 3°C-cold water. Volunteers were asked to submerge their hands in the cold water for as long as they could manage. Dependent measures of the Cold Pressor Test include pain tolerance (i.e. the duration for which participants can hold their hand in the tank) and subjective ratings of painfulness, unpleasantness and stress.
    [Show full text]
  • Global Cannabis Research Leaders Beckley Foundation & Canopy Growth Partner to Form Beckley Canopy Therapeutics
    GLOBAL CANNABIS RESEARCH LEADERS BECKLEY FOUNDATION & CANOPY GROWTH PARTNER TO FORM BECKLEY CANOPY THERAPEUTICS April 2, 2018 SMITHS FALLS, ON & OXFORD, UK – Canopy Health Innovations (“Canopy Health”), the biopharmaceutical research and development arm and partly-owned subsidiary of Canopy Growth Corporation (TSX: WEED) ("Canopy Growth"), is pleased to announce the launch of Beckley Canopy Therapeutics (“Beckley Canopy”), a partnership with drug research pioneer Lady Amanda Feilding, and the Beckley Foundation. Beckley Canopy is designed to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. The partnership will combine Amanda Feilding’s 20+ year track record of groundbreaking research and network of world-renowned scientific collaborators with Canopy’s leadership in the commercial cannabis and pharmaceutical industries, bringing together European and North-American based research leaders in cannabis. “We are delighted to have formed this partnership with Beckley. They have been leading the way in drug policy reform and cannabis research for more than two decades and we feel that our skill-sets complement each other perfectly,” said Marc Wayne, CEO of Canopy Health. “This is a unique opportunity to expand our operations, conduct world- class research, and meet the needs of doctors and patients around the world.” Beckley Canopy's business model is to engage in a number of research areas in order to enhance its intellectual property portfolio and develop innovative cannabis products for the pharmaceutical and nutraceutical markets. In doing so, it plans to work with cannabis genetics and other products provided by its strategic partner, Canopy Growth, the largest cannabis company in the world.
    [Show full text]
  • Idpc Drug Policy Guide 3Rd Edition
    IDPC DRUG POLICY GUIDE 3RD EDITION IDPC Drug Policy Guide 3 IDPC DRUG POLICY GUIDE 3RD EDITION Acknowledgements Global Drug Policy Observatory) • Dave Borden (StoptheDrugWar.org) IDPC would like to thank the following authors for drafting chapters of the 3rd Edition of the • Eric Gutierrez (Christian Aid) IDPC Drug Policy Guide: • Fabienne Hariga (United Nations Office on • Andrea Huber (Policy Director, Penal Reform Drugs and Crime) International) • George McBride (Beckley Foundation) • Benoit Gomis (Independent international • Gloria Lai (IDPC) security analyst, Associate Fellow at Chatham House, and Research Associate at Simon Fraser • Graham Bartlett (former Chief Superintendent University) of the Sussex Police) • Christopher Hallam (Research Officer, IDPC) • Gregor Burkhart (European Monitoring Centre for Drugs and Drug Addiction) • Coletta Youngers (Consultant, IDPC & Washington Office on Latin America) • Ines Gimenez • Diana Guzmán (Associate investigator, • Jamie Bridge (IDPC) DeJusticia, Associate Professor at Colombian • Javier Sagredo (United Nations Development National University and PhD candidate at Program) Stanford University) • Jean-Felix Savary (Groupement Romand • Diederik Lohman (Associate Director, Health d’Etudes en Addictologie) and Human Rights Division, Human Rights • Juan Fernandez Ochoa (IDPC) Watch) • Katherine Pettus (International Association for • Gloria Lai (Senior Policy Officer, IDPC) Hospice and Palliative Care) • Jamie Bridge (Senior Policy and Operations Manager, IDPC) • Luciana Pol (Centro de Estudios
    [Show full text]
  • War on Drugs: Report of the Global Commission on Drug Policy
    WAR ON DRUGS REPORT OF THE GLOBAL COMMISSION ON DRUG POLICY JUNE 2011 REPORT OF THE COMMISSIONERS GLOBAL COMMISSION Asma Jahangir, human rights activist, former UN Special Rapporteur on Arbitrary, Extrajudicial and ON DRUG POLICY Summary Executions, Pakistan Carlos Fuentes, writer and public intellectual, Mexico César Gaviria, former President of Colombia Ernesto Zedillo, former President of Mexico Fernando Henrique Cardoso, former President of To learn more about the Commission, visit: Brazil (chair) www.globalcommissionondrugs.org George Papandreou, Prime Minister of Greece Or email: [email protected] George P. Shultz, former Secretary of State, United States (honorary chair) Javier Solana, former European Union High Representative for the Common Foreign and Security Policy, Spain John Whitehead, banker and civil servant, chair of the World Trade Center Memorial Foundation, United States Kofi Annan, former Secretary General of the United Nations, Ghana Louise Arbour, former UN High Commissioner for Human Rights, President of the International Crisis Group, Canada Maria Cattaui, Petroplus Holdings Board member, former Secretary-General of the International Chamber of Commerce, Switzerland Mario Vargas Llosa, writer and public intellectual, Peru Marion Caspers-Merk, former State Secretary at the German Federal Ministry of Health Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, France Paul Volcker, former Chairman of the United States Federal Reserve and of the Economic Recovery Board Richard Branson, entrepreneur, advocate for social causes, founder of the Virgin Group, co-founder of The Elders, United Kingdom Ruth Dreifuss, former President of Switzerland and Minister of Home Affairs Thorvald Stoltenberg, former Minister of Foreign Affairs and UN High Commissioner for Refugees, Norway EXECUTIVE SUMMARY The global war on drugs has failed, with Our principles and recommendations can devastating consequences for individuals be summarized as follows: and societies around the world.
    [Show full text]
  • Amanda Feilding and the Beckley Foundation
    BECKLEY FOUNDATION SCIENTIFIC PROGRAMME 2017 1 ha The Beckley Foundation is a UK-based think tank and UN-accredited NGO founded by Amanda Feilding in 1998. We conduct pioneering scientific research in order to further our understanding of consciousness and reveal the mechanisms underlying the medical and cognitive benefits of psychedelics, cannabis and MDMA. We advocate the legal regulation of all drugs in order to reduce harms at all stages of the supply chain. Combining science and policy, we are driving evidence-based drug policy reform on a global level. The Scientific Programme, led by Amanda, The Policy Programme brings together leading develops and conducts psychedelic international scientists, politicians and experts research through an international network to provide a rigorous, independent review of collaborative partnerships with leading of current global drug policies and develop scientists and institutions. Studies focus on a scientific evidence-base on which to build cannabis, psychedelics (psilocybin, LSD, balanced alternatives. We convene seminars ayahuasca, DMT, and 5MeO-DMT), and and produce policy reports to shed light on the MDMA. We investigate the action of these taboo issues around this complex subject, and substances in the human brain, using the demonstrate how the legal regulation of drug latest developments in neuroscience and brain markets can reduce the harms caused by both imaging technology. Our research and clinical the drugs themselves and by the collateral trials aim to increase our understanding of consequences of prohibition. We collaborate consciousness, and to use this knowledge globally with political leaders – most recently to treat mental and physical illness, expand advising the Jamaican government in creating awareness, and enhance well-being and its emerging cannabis industry.
    [Show full text]
  • BF Achievements Brochure
    THE BECKLEY FOUNDATION History and Achievements Exploring Consciousness Pioneering Research Changing Minds BECKLEY FOUNDATION SCIENTIFIC ADVISORY BOARD t SIR COLIN BLAKEMORE , PH.D., FI.BIOL., F.MED.SCI., HON F.R.C.P., F.R.S. Former Chief Executive of the Medical Research Council (MRC). Emeritus Professor of Neuroscience at the University of Oxford. PROF. GUSTAV BORN, M.A., D.PHIL., F.R.C.P., F.R.S., F.K.C. Emeritus Professor of Pharmacology at King’s College London. PROF. GORDON CLARIDGE, PH.D., D.SC. Emeritus Professor of Abnormal Psychology, University of Oxford and Fellow of the British Psychological Society. PROF. VALERIE CURRAN, PH.D. Professor of Psychopharmacology at University College London. Principal Editor of Psychopharmacology since 2003. PROF. MARK GEYER, PH.D. Distinguished Professor of Psychiatry and Neurosciences and Vice-Chair for Scientific Affairs in Psychiatry at the University of California, San Diego. PROF. LESTER GRINSPOON, M.D. Associate Professor Emeritus of Psychiatry at Harvard Medical School. Fellow of the American Association of the Advancement of Science and the Editor of American Psychiatric Association Annual Review. PROF. LESLIE L. IVERSEN, PH.D., F.R.S. Chair of the Advisory Council on the Misuse of Drugs, UK, and Visiting Professor of Pharmacology, University of Oxford. Former Director of the MRC Neurochemical Pharmacology Unit, Cambridge. PROF. YURI E. MOSKALENKO, PH.D. Head of Laboratory, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences. PROF. DAVID E. NICHOLS, PH.D. Emeritus Professor of Pharmacology, Purdue University, USA, and Adjunct Professor at the University of North Carolina, Chapel Hill, NC.
    [Show full text]